Towards Healthcare Research & Consulting

Metformin - Uses, Warnings, Before taking, Dosage, Side effects and Interactions

Published:11 September 2026  |  Author: Towards Healthcare  |   |  Copy Copy   Print Print

Metformin is an oral medicine belonging to the biguanide class and is widely used to improve blood glucose control in people with type 2 diabetes mellitus. used for the management of hyperglycemia in patients with type 2 diabetes mellitus. Its mechanism of action includes the reduction of glucose production by the liver and increasing the sensitivity of the body to insulin. The drug can be taken in two forms, immediate-release and extended-release tablets, and is commonly used with the help of dietary and physical activities.

Important Warnings While Taking Metformin

The major caution related to metformin involves the development of lactic acidosis, which is a rare and sometimes life-threatening condition characterized by excess accumulation of lactic acid in the blood. People at higher risk for developing the condition are those with renal impairment, hepatic impairment, heavy consumption of alcohol, cardiac problems, respiratory dysfunction, advanced age, and certain types of medical procedures. The symptoms of the condition may be nonspecific and include unexpected fatigue or weakness, muscle pain, difficulty breathing, drowsiness, abdominal distress, or feeling sick without knowing the cause. Any suspicion of developing lactic acidosis must prompt immediate medical attention and discontinuation of use of metformin.

Metformin should not be prescribed in case of severe renal insufficiency. In addition, a kidney function test is required before starting the therapy and subsequently as needed during the course of treatment. According to the present labeling of extended-release metformin from the Food and Drug Administration, it should not be started if eGFR is between 30-45 mL/min/1.73 m², and discontinued if eGFR is less than 30 mL/min/1.73 m².

Metformin may also need to be temporarily stopped around certain iodinated contrast imaging procedures, depending on kidney function and the specific clinical situation. Healthcare professionals should be informed that the patient is taking metformin before such procedures.

Things to consider before Metformin consumption

Before starting metformin, the following factors should be discussed with a healthcare professional:

In patients with a history or renal function should be assessed before treatment because impaired clearance can increase metformin exposure and the risk of lactic acidosis, which is a concerning point. Hepatic impairment and kidney-related issues may increase the risk associated with lactic acidosis, and current labeling advises avoiding some extended-release metformin formulations in patients with hepatic impairment. Excessive alcohol intake can increase the risk of metformin-associated lactic acidosis.

Conditions associated with hypoxia, including certain forms of acute heart failure, may increase risk, and conditions related to oxygen and the heart must be reported to the doctor for effective treatment. Metformin may need to be temporarily withheld around certain procedures that require surgery or related procedures. Other major factors include vitamin B12 monitoring and other medicine interaction which may affect kidney function, requiring additional monitoring or dose adjustments.

Application/Consumption

It is taken orally in combination with a well-controlled diet and exercise routine. Immediate-release metformin is usually taken during meals in order to decrease side effects in the stomach. The extended-release form is typically taken with an evening meal, but it can vary according to specific medication prescriptions.

The drug must be taken in accordance with a doctor's prescription. In general, extended-release tablets should not be crushed, cut, or chewed since modification may affect the drug release. For instance, the labeling of Glumetza by the FDA recommends taking one dose per day at dinner time and swallowing the tablet whole.

In case of missing a dose, one should follow the recommendations of the specific formulation and should not take additional medicine in order to make up the missed dose. It should not be discontinued or modified without consulting a health care provider since glucose levels in the blood can increase with the interruption of the therapy.

Dosing information

Metformin dosing varies according to the formulation, blood glucose response, tolerability, kidney function, age, and other diabetes medicines being used.

Uses

Metformin is primarily used for: 

  • Type 2 diabetes mellitus 
  • Combination diabetes therapy
  • Insulin resistance-related conditions
  • Long-term glucose management

Metformin is not the medicine for diabetic ketoacidosis, and it is not used for treating type 1 diabetes. Its FDA-approved use is mainly for improving glycaemic control in type 2 diabetes. It is used along with proper diets and exercise, which help control the levels of glucose in the blood. It is also used along with other medicines, which help reduce glucose levels. Proper monitoring and regulation of glucose levels by the patient are required to ensure proper management of the medication, and if any fluctuations occur during medication, consultation with a doctor is recommended.

Metformin side effects

  • Diarrhea
  • Nausea and vomiting
  • Gas and bloating
  • Metallic taste
  • Mild fatigue or headache
  • Vitamin B12 deficiency
  • Lactic acidosis

Common adverse effects associated with metformin therapy are related to the gastrointestinal tract. Side effects include diarrhea, nausea, vomiting, abdominal pain, flatulence, indigestion, or alteration of stool. Ingestion of metformin with food and a gradual increase in the dosage may reduce the adverse effects on the gastrointestinal tract.

Metformin can be a reason for decreased appetite or altered taste sensation. This effect usually becomes less pronounced with time. Severe or persistent gastrointestinal side effects require consulting the prescribing healthcare provider.

Metformin has an effect on vitamin B12 levels. Metformin-induced vitamin B12 deficiency is mentioned in current FDA labeling as a precaution. Therefore, healthcare providers should consider regular monitoring of patients under long-term metformin therapy or those with symptoms/risk factors of vitamin B12 deficiency. 

One of the uncommon but severe side effects is lactic acidosis. Symptoms of warning include extreme fatigue, muscle pain, difficulty breathing, excessive sleeping, stomach pain, or feeling ill. The condition is more likely among individuals with advanced kidney disease, excessive consumption of alcohol, liver disease, hypoxia, or other known risks.

Metformin alone usually has low potential for inducing hypoglycemia since it does not act on pancreatic cells to produce insulin. When taking metformin in combination with insulin and insulin secretagogues, however, the patient may experience hypoglycemia. Metformin use requires regular monitoring of blood glucose levels, especially when used with combination therapy.

Drug interaction and renal function are factors that need to be assessed on a periodic basis. The drug could be withheld temporarily before iodinated contrast procedures or surgery and then resumed.

Key Insights

In April 2026, Lupin Limited launched its generic Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States. The commercial rollout immediately followed regulatory approval from the U.S. FDA for the company's Abbreviated New Drug Application (ANDA). Lupin introduced all four primary dosing strengths utilized by clinicians to give patients complete flexibility when transitioning from the branded version to the more affordable generic option.

https://www.lupin.com/media/press-releases/lupin-launches-dapagliflozin-and-metformin-hydrochloride-extended-release-tablets-in-the-united-states

In June 2026, Apotex Corp. officially announced the U.S. commercial launch of its generic Sitagliptin Tablets and Sitagliptin and Metformin Hydrochloride Tablets. This milestone makes Apotex the first generic manufacturer to publicly confirm a U.S. launch for these formulations, entering the market ahead of other major developers.

https://www.apotex.com/global/news/news-release/2026/06/03/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity

 In July 2026, Par Health, Inc. announced the official U.S. commercial launch of its generic version of Merck’s blockbuster type 2 diabetes drug, Janumet XR (sitagliptin and metformin HCl extended-release) tablets. This rollout represents a highly lucrative milestone, as Par Health entered the market as the first and only FDA-approved generic equivalent to Janumet XR available in the United States.

https://www.prnewswire.com/news-releases/par-health-launches-first-and-only-generic-version-of-janumet-xr-sitagliptin-and-metformin-hcl-extended-release-tablets-in-the-united-states-302833758.html